following a full submission:
cariprazine (Reagila®) is accepted for restricted use within NHSScotland.
Indication under review: the treatment of schizophrenia in adult patients.
SMC restriction: for use as a second-line therapy in patients where predominantly negative symptoms have been identified as an important feature.
In patients with stable schizophrenia with predominantly negative symptoms, cariprazine improved negative symptoms more than another second-generation antipsychotic.
To read more Press Release articles, click here.